Jiangsu Sinopep-Allsino Biopharmaceutical (SH:688076) 智通财经网·2025-07-31 08:48Core Viewpoint - ST诺泰 has received approval from the National Medical Products Administration for the registration certificates of injectable Acetate Cetrorelix and Agomelatine tablets, indicating significant advancements in their product offerings in the reproductive health and mental health sectors [1]. Group 1: Product Approvals - The approval includes Acetate Cetrorelix, a third-generation GnRH antagonist, which shows unique clinical advantages in assisted reproductive technology compared to other similar drugs [1]. - Acetate Cetrorelix demonstrates superior onset speed, safety (prevention of OHSS), shorter treatment cycles, and better patient tolerance compared to GnRH agonists [1]. - Compared to other antagonists like Ganirelix, Acetate Cetrorelix has milder injection reactions, making it an efficient and flexible choice in assisted reproduction [1]. Group 2: Agomelatine's Unique Position - Agomelatine is a novel antidepressant with a unique dual mechanism of action, distinguishing it from common antidepressants such as SSRIs and SNRIs [1]. - It is the only antidepressant that can rapidly improve sleep without affecting daytime functioning, addressing a critical need in the market [1]. - Agomelatine has a very low risk of sexual dysfunction, minimal impact on weight, good tolerance, and fewer withdrawal reactions, securing an important position in the market for depression with insomnia [1].